Literature DB >> 18781376

Effect of sibutramine HCl on cardiac hERG K+ channel.

Ki-Suk Kim1, Eun-Joo Kim, Hyang-Ae Lee, Sang-Joon Park.   

Abstract

Common clinically used drugs block the delayed rectifier K(+) channels and prolong the cardiac action potential duration associated with long QT syndrome. Here, we investigated the mechanism of hERG K(+) channel current (I(hERG)) blockade expressed in HEK-293 cells by sibutramine HCl, a serotonin-norepinephrine reuptake inhibitor. Sibutramine HCl inhibited I (hERG) in a concentration-dependent manner with the half-maximal inhibitory concentration (IC(50)) value of 2.5 microM at -40 mV. I(hERG) inhibition by sibutramine HCl showed weak voltage dependency, but the time-dependence of I(hERG) inhibition was developed relatively rapidly on membrane depolarization. On hERG channel gating for the S6 and pore regions, the S6 residue hERG mutant Y652A and F656A largely reduced the blocking potency of I(hERG), unlike the pore-region mutants T623A and S624A. These results indicate that sibutramine HCl preferentially inhibits the hERG potassium channel through the residue Y652 and F656, in a supratherapeutic concentration should be avoided by patients with high susceptibility for cardiac arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781376     DOI: 10.1007/s11010-008-9914-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  13 in total

1.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.

Authors:  J P Lees-Miller; Y Duan; G Q Teng; H J Duff
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

Review 2.  Sibutramine: a novel new agent for obesity treatment.

Authors:  D H Ryan; P Kaiser; G A Bray
Journal:  Obes Res       Date:  1995-11

Review 3.  Priorities and standards in pharmacogenetic research.

Authors:  Anna C Need; Arno G Motulsky; David B Goldstein
Journal:  Nat Genet       Date:  2005-07       Impact factor: 38.330

4.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.

Authors:  Dierk Thomas; Bernd Gut; Gunnar Wendt-Nordahl; Johann Kiehn
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

5.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

6.  Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.

Authors:  P S Spector; M E Curran; M T Keating; M C Sanguinetti
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

7.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  QT interval prolongation associated with sibutramine treatment.

Authors:  Mira Harrison-Woolrych; David W J Clark; Geraldine R Hill; Mark I Rees; Jonathan R Skinner
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

9.  A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.

Authors:  M C Sanguinetti; C Jiang; M E Curran; M T Keating
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

10.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.

Authors:  M E Curran; I Splawski; K W Timothy; G M Vincent; E D Green; M T Keating
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  3 in total

1.  Cardiac arrest caused by sibutramine obtained over the Internet: a case of a young woman without pre-existing cardiovascular disease successfully resuscitated using extracorporeal membrane oxygenation.

Authors:  Naofumi Bunya; Keigo Sawamoto; Shuji Uemura; Ryoko Kyan; Hiroyuki Inoue; Junichi Nishida; Hidemichi Kouzu; Nobuaki Kokubu; Tetsuji Miura; Eichi Narimatsu
Journal:  Acute Med Surg       Date:  2017-03-29

2.  The molecular determinants of R-roscovitine block of hERG channels.

Authors:  Bryan Cernuda; Christopher Thomas Fernandes; Salma Mohamed Allam; Matthew Orzillo; Gabrielle Suppa; Zuleen Chia Chang; Demosthenes Athanasopoulos; Zafir Buraei
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

3.  An in Vitro Assay of hERG K + Channel Potency for a New EGFR Inhibitor FHND004.

Authors:  Tao Jin; Bingxue Hu; Shanshan Chen; Qiang Wang; Xue Dong; Yin Zhang; Yongqiang Zhu; Zhao Zhang
Journal:  Front Pharmacol       Date:  2018-05-31       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.